These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
441 related articles for article (PubMed ID: 30903538)
1. New antimicrobial options for the management of complicated intra-abdominal infections. Leone S; Damiani G; Pezone I; Kelly ME; Cascella M; Alfieri A; Pace MC; Fiore M Eur J Clin Microbiol Infect Dis; 2019 May; 38(5):819-827. PubMed ID: 30903538 [TBL] [Abstract][Full Text] [Related]
2. New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance. Syue LS; Chen YH; Ko WC; Hsueh PR Int J Antimicrob Agents; 2016 Apr; 47(4):250-8. PubMed ID: 27005457 [TBL] [Abstract][Full Text] [Related]
3. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684 [TBL] [Abstract][Full Text] [Related]
4. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents. Bader MS; Loeb M; Leto D; Brooks AA Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743 [TBL] [Abstract][Full Text] [Related]
5. Recent developments in antibiotic agents for the treatment of complicated intra-abdominal infections. Lin SY; Huang CH; Ko WC; Chen YH; Hsueh PR Expert Opin Pharmacother; 2016; 17(3):339-54. PubMed ID: 26610040 [TBL] [Abstract][Full Text] [Related]
6. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms. Sharma R; Park TE; Moy S Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI). Kongnakorn T; Eckmann C; Bassetti M; Tichy E; Di Virgilio R; Baillon-Plot N; Charbonneau C Antimicrob Resist Infect Control; 2019; 8():204. PubMed ID: 31890160 [TBL] [Abstract][Full Text] [Related]
8. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI). Solomkin J; Hershberger E; Miller B; Popejoy M; Friedland I; Steenbergen J; Yoon M; Collins S; Yuan G; Barie PS; Eckmann C Clin Infect Dis; 2015 May; 60(10):1462-71. PubMed ID: 25670823 [TBL] [Abstract][Full Text] [Related]
9. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections. Nicolau DP Expert Opin Investig Drugs; 2015; 24(9):1261-73. PubMed ID: 26145447 [TBL] [Abstract][Full Text] [Related]
10. Aztreonam-avibactam for the treatment of intra-abdominal infections. Delp H; Gibson GA; Buckman SA Expert Opin Pharmacother; 2024 Oct; 25(14):1867-1872. PubMed ID: 39327993 [TBL] [Abstract][Full Text] [Related]
11. What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam? Gentile I; Maraolo AE; Borgia G Expert Rev Anti Infect Ther; 2016 Oct; 14(10):875-8. PubMed ID: 27599088 [No Abstract] [Full Text] [Related]
12. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn? Wright H; Bonomo RA; Paterson DL Clin Microbiol Infect; 2017 Oct; 23(10):704-712. PubMed ID: 28893690 [TBL] [Abstract][Full Text] [Related]
13. Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections. Eckmann C; Solomkin J Expert Opin Pharmacother; 2015 Feb; 16(2):271-80. PubMed ID: 25529765 [TBL] [Abstract][Full Text] [Related]
14. Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination. Sucher AJ; Chahine EB; Cogan P; Fete M Ann Pharmacother; 2015 Sep; 49(9):1046-56. PubMed ID: 26160970 [TBL] [Abstract][Full Text] [Related]
15. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections. Kanj SS; Bassetti M; Kiratisin P; Rodrigues C; Villegas MV; Yu Y; van Duin D Int J Antimicrob Agents; 2022 Sep; 60(3):106633. PubMed ID: 35787918 [TBL] [Abstract][Full Text] [Related]
16. A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia. Qin X; Tran BG; Kim MJ; Wang L; Nguyen DA; Chen Q; Song J; Laud PJ; Stone GG; Chow JW Int J Antimicrob Agents; 2017 May; 49(5):579-588. PubMed ID: 28363526 [TBL] [Abstract][Full Text] [Related]
17. New β-lactam-β-lactamase inhibitor combinations in clinical development. Shlaes DM Ann N Y Acad Sci; 2013 Jan; 1277():105-14. PubMed ID: 23346860 [TBL] [Abstract][Full Text] [Related]
18. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Bush K Int J Antimicrob Agents; 2015 Nov; 46(5):483-93. PubMed ID: 26498989 [TBL] [Abstract][Full Text] [Related]
19. [New Antibiotics for Treatment of Highly Resistant Gram-negative Bacteria]. Probst-Kepper M; Geginat G Anasthesiol Intensivmed Notfallmed Schmerzther; 2018 Jul; 53(7-08):529-542. PubMed ID: 30036899 [TBL] [Abstract][Full Text] [Related]
20. Ceftazidime-avibactam for the treatment of complicated intra-abdominal infections. Buckman SA; Krekel T; Muller AE; Mazuski JE Expert Opin Pharmacother; 2016 Dec; 17(17):2341-2349. PubMed ID: 27758148 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]